Markets
Airplane Pilot Whispering To Woman
(Getty Images)

The dirty little secret about European stocks

They need to be hated before they’ll show investors some love.

Luke Kawa

A surprising re-emergence of European political risk has crushed stocks on the continent.

Heading into this week, the benchmark Euro Stoxx 50 Index was down about 3% in the trailing three months, while the MSCI World Index of developed-market countries was up nearly 4% over the same period.

It’s reached the point where France — the largest equity market among European Union nations and the epicenter of the current drama — has a lower market capitalization than Nvidia.

But there may be a silver lining in this drubbing for European stock bulls. Or rather, for investors who might be considering becoming European stock bulls: that Europe’s pain seems to be one of the few reliable path’s to Europe’s gain.

Three stretches of sharp European stock outperformance come to mind over the past dozen years:

  • Mid-2012: A reaction to European Central Bank President Mario Draghi’s pronouncement that he’d do “whatever it takes to preserve the euro” as sovereign debt crises raged. Not too long before this, European stocks lagged the MSCI World by nearly 10% over a three-month period.

  • Late 2014-early 2015: In the run-up to the ECB’s quantitative easing program (which itself was a reaction to relatively sluggish economic activity). The euro was slammed during, falling more than 10% versus the US dollar. That takes some of the bloom off the rose.

  • Late 2022-early 2023: Russia’s invasion of Ukraine caused energy price spikes that crippled European industry and raised concerns that governments would be able to secure the necessary supplies to keep their populace warm in the winter. These concerns turned out to be overblown and European stocks enjoyed a significant relief rally.

A resolution of the last time we had high political drama in French — the election that brought President Emmanuel Macro to power — also helped spur a little mini-boom for European bourses.

So Euro-centric carnage, and/or worries that some are on the way, seem to be a prerequisite for meaningful episodes of future outperformance. (That, or a US market bust like the end of the dot-com bubble.)

Why are European equities cursed with needing to be hated before they can be loved?

The reason, in my eyes, is pretty simple: Europe has had a lost generation for earnings growth. 12-month forward earnings per share estimates for the Euro Stoxx 50 are still below their 2008 peak. Meanwhile, the MSCI World’s forward 12-month EPS projection is 60% above its pre-GFC peak.

Most top-down macro managers look at a mix of valuation, macroeconomic, and technical (a mix of behavioral, positioning, and momentum) factors when determining where to put their money to work. Europe has virtually always had valuation in its favor (to little avail), but rarely macro. And the technicals really only seem become favorable when the region is so unloved that it won’t take much in the way of positive news to help. In other words, when it’s a contrarian bet.

It’s not clear (and really, a little doubtful) that the current bout of turmoil is on the same scale of what was facing Europe during the myriad sovereign debt crises of 2011-2012 or heading into the winter of 2022, despite the discordant price action between Europe and its developed-market peers as of late. But the drama may promise to deepen no matter who’s able to form a government after these elections.

While American markets had the day off on Wednesday, France and a handful of other countries in the region were chastised by the European Commission for running fiscal deficits that run afoul of EU rules.

“This might seem insignificant for markets given we already knew about the deficit issue and it was priced in,” writes Deutsche Bank macro strategist Jim Reid. “But it’s particularly important right now, because we’ve got the French parliamentary elections on June 30 and July 7, where both Marine Le Pen’s National Rally and the left-wing alliance have indicated that they’d take a more assertive stance against the EU, raising the risk of more clashes over the months ahead.”

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.